Antibody Contract Manufacturing Market
Antibody Contract Manufacturing Market Analysis by Monoclonal Antibodies, Antibody Fragments, and Polyclonal Antibodies for Preclinical, Clinical, and Commercial from 2024 to 2034
Analysis of Antibody Contract Manufacturing Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Antibody Contract Manufacturing Market Outlook (2024 to 2034)
The global antibody contract manufacturing market size is calculated at a size of US$ 6.1 billion for 2024 and is forecasted to reach US$ 20.85 billion by the end of 2034, expanding at a double-digit CAGR of 13.1%.
Antibody contract manufacturing is at the forefront of the biopharmaceutical industry, serving as an essential element in the production of monoclonal antibodies (mAbs) and antibody fragments, which are critical components in therapeutic interventions.
The market is centered on the outsourcing of antibody production to specialized healthcare contract manufacturing organizations (CMOs) with advanced infrastructure, knowledge, and technology. Because of the complexities of antibody production and growing emphasis on precision medicine, demand for these contract services has increased.
Antibody contract manufacturing is a critical component of the biopharmaceutical industry that focuses on antibody production through contract manufacturing organizations (CMOs). These organizations specialize in the creation and manufacturing of antibodies for pharmaceutical and biotech firms, hence streamlining production.
Antibodies, also known as immunoglobulins, are essential components of the immune system, recognizing and neutralizing foreign molecules such as bacteria, viruses, and other pathogens. Demand for biological drugs has been gradually increasing due to a variety of variables, including the increased prevalence of chronic diseases such as cancer, autoimmune disorders, and infectious diseases.
Key Market Growth Drivers
- Escalating prevalence of chronic diseases and the demand for targeted therapies have fueled the need for biologic injectors, amplifying the need for antibody manufacturing.
- Innovations in bioprocessing techniques, such as single-use technologies and cell culture systems, have enhanced manufacturing efficiency, reducing production costs and time.
- Shift toward personalized medicine and the development of monoclonal antibodies tailored to individual patients drive the antibody contract manufacturing market growth.
- Pharmaceutical and biotech companies prefer outsourced manufacturing by CMOs to focus on core competencies, thereby reducing infrastructure costs and gaining access to specialized expertise.
- Stringent regulations necessitate compliance with quality standards and good manufacturing practices (GMP), encouraging companies to collaborate with experienced CMOs to ensure regulatory compliance.
| Report Attributes | Details |
|---|---|
| Antibody Contract Manufacturing Market Size (2023A) | US$ 5.39 Billion |
| Estimated Market Value (2024E) | US$ 6.1 Billion |
| Forecasted Market Value (2034F) | US$ 20.85 Billion |
| Global Market Growth Rate (2024 to 2034) | 13.1% CAGR |
| East Asia Market Share (2034F) | 38.4% |
| Monoclonal Antibodies Segment Growth Rate (2024 to 2034) | 13.2% CAGR |
| Key Companies Profiled |
|
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Why is Demand for Antibody Contract Manufacturing Rising Rapidly?
“Rising Demand for Personalized Medicine and Advancements in Biotechnology and Genetic Sequencing”
Surge in personalized medicine stands as a pivotal driver propelling the expansion of the antibody contract manufacturing market size. A personalized treatment approach that takes into account the genetic makeup of the patient, lifestyle, and disease characteristics is being adopted by the healthcare industry.
Due to their capacity to target particular antigens, antibodies such as monoclonal antibodies, play a critical role in this new paradigm. The ability to identify particular biomarkers and molecular targets has allowed researchers and clinicians to make significant progress toward developing highly targeted antibody-based therapies.
A personalized approach improves treatment effectiveness while minimizing harmful side effects by precisely targeting the agents causing diseases.
Pharmaceutical and biotech companies increasingly rely on contract manufacturing organizations (CMOs) to produce these specialized antibodies, driving the demand for efficient and scalable manufacturing solutions capable of meeting the unique needs of personalized medicine.
“Technological Advancements and Integration of Automation in Antibody Contract Manufacturing”
Continuous evolution of bioprocessing technologies and techniques has revolutionized the manufacturing landscape, enhancing efficiency, scalability, and cost-effectiveness. Innovations in cell culture systems, purification methods, and single-use technologies have significantly streamlined antibody production processes. These advancements have not only expedited manufacturing timelines but also improved product quality and yield.
Integration of automation, data analytics, and artificial intelligence (AI) in manufacturing processes has optimized production, ensuring consistency and compliance with stringent regulatory standards. The ability to scale up production while maintaining product quality has become a hallmark of success in antibody manufacturing. Pharmaceutical and biotech companies seek partnerships with CMOs equipped with cutting-edge technologies and expertise to capitalize on these advancements and meet the escalating demand for high-quality antibody therapeutics.
Which Factors are Affecting Revenue Growth from Antibody Contract Manufacturing?
“High Initial Investments in Cutting-edge Technology and Complex Production Process”
Initial capital investment required for establishing state-of-the-art manufacturing facilities, acquiring cutting-edge technology, and ensuring compliance with stringent regulatory standards poses a formidable barrier. These costs encompass not only infrastructure development but also specialized equipment, skilled labor, and adherence to strict quality control measures.
Complexities associated with scaling up production to meet market demands amplify these expenses, often straining the financial resources of emerging players. The expense of maintaining adherence to regulatory compliance throughout the manufacturing process adds to the overall production costs.
Need for continual investment in research and development to improve manufacturing efficiency and optimize processes further contributes to the financial burden. Overcoming these cost barriers necessitates strategic collaborations, innovative cost-saving approaches, and possibly governmental incentives to foster a more accessible entry point for emerging businesses in the antibody contract manufacturing landscape.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
What Strategies Can Start-ups Employ to Enhance Their Antibody Production?
“Focus on Establishing Credibility and Client Relationships”
Forging strategic partnerships or collaborations with established CMOs or larger biopharmaceutical companies can be a game-changer for start-ups. Such alliances grant access to critical manufacturing expertise, specialized facilities, and regulatory insights, allowing start-ups to leverage existing infrastructure and knowledge. Specializing in specific antibody types, innovative manufacturing technologies, or addressing unmet needs in the production process can set them apart.
Enabling quick adaptation to changing market demands and technological advancements aids start-ups in gaining a competitive edge. Start-ups must prioritize research and development investments to drive innovation. Strong adherence to quality standards and regulatory compliance is equally important, as the biopharmaceutical industry depends heavily on these strict regulations. Start-ups can establish credibility and cultivate long-term client relationships by developing a reputation for dependability, efficiency, and cost-effectiveness while providing high-quality products and services.
Country-wise Insights
Regional antibody contract manufacturing trends are important in this market. North America is at the forefront because it focuses on biopharmaceutical companies and an excellent regulatory framework. Biotechnology research and development is a key focus in Europe. East Asia continues to grow as a profitable market for players, propelled by considerable biopharmaceutical expenditures and a growing emphasis on technical innovation.
How is the Market for Antibody Formulation Shaping Up in the United States?
“High Focus on Providing Comprehensive and Advanced Solutions to Biopharmaceutical Production Companies”
| Attribute | United States |
|---|---|
| Market Value (2024E) | US$ 1.87 Billion |
| Growth Rate (2024 to 2034) | 11.4% CAGR |
| Projected Value (2034F) | US$ 5.5 Billion |
The U.S. has a favorable regulatory environment that emphasizes quality standards and Good Manufacturing Practices (GMP). This regulatory environment not only ensures strict oversight but also incentivizes companies to seek out experienced CMOs for their manufacturing needs, driving market growth.
The United States is at the forefront of technological innovation, which enhances production efficiency, reduces costs, and speeds up the manufacturing process.
This knowledge positions the country as a leader in providing high-quality, efficient, and scalable antibody production services to both domestic and foreign clients. The United States has a competitive advantage due to its solid infrastructure and access to highly skilled professionals in pharmaceutical sciences, biotechnology, and bioengineering. This enables the development of cutting-edge manufacturing facilities outfitted with cutting-edge technology.
Why is Demand for Antibody Contract Manufacturing Increasing Rapidly in China?
“Proactive Government Measures and Funding Initiatives and Cost-Effective Labor Force”
| Attribute | China |
|---|---|
| Market Value (2024E) | US$ 1.19 Billion |
| Growth Rate (2024 to 2034) | 17.2% CAGR |
| Projected Value (2034F) | US$ 5.81 Billion |
Proactive measures of China to bolster its biotech industry, coupled with supportive government policies and funding initiatives, have propelled the nation into a prominent position within the global pharmaceutical landscape. With an expanding domestic market and an increasing demand for innovative biologic drugs to address healthcare needs, China has strategically positioned itself to meet this demand through advanced manufacturing capabilities.
Cost-effective labor force and manufacturing infrastructure offer a competitive edge, attracting multinational pharmaceutical companies seeking efficient and economical production solutions. Emphasis on research and development, combined with its growing pool of skilled scientific talent, fosters a conducive environment for innovation in biopharmaceuticals, including antibody manufacturing.
Favorable regulatory reforms in China have streamlined the approval process for biologic drugs and manufacturing facilities, encouraging both domestic and international companies to invest in antibody contract manufacturing within the region. The commitment of the government to enhance intellectual property protection further boosts investor confidence, attracting foreign collaborations and partnerships to leverage expanding expertise in antibody manufacturing in China.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Category-wise Insights
Monoclonal antibodies lead the market because of their varied therapeutic applications and excellent specificity. Demand for antibody contract manufacturing services is driven by a variety of end users, including pharmaceutical companies, biotechnology enterprises, academic research institutes, and contract research organizations.
Why are Monoclonal Antibodies in Such High Demand?
“Exceptional Specificity and Scalability of Monoclonal Antibodies”
| Attribute | Monoclonal Antibodies |
|---|---|
| Segment Value (2024E) | US$ 5.44 Billion |
| Growth Rate (2024 to 2034) | 13.2% CAGR |
| Projected Value (2034F) | US$ 18.82 Billion |
Monoclonal antibodies (mAbs) stand as the leading product within the antibody contract manufacturing industry due to their exceptional versatility, specificity, and widespread therapeutic applications. Antibodies developed from identical immune cells that are clones of a single parent cell offer precision targeting of specific antigens, making them highly effective in treating various diseases.
The specificity of antibodies allows for tailored approaches to tackle conditions such as cancer, autoimmune disorders, and infectious diseases. The success of mAbs lies in their ability to bind to specific targets with high affinity, reducing off-target effects and minimizing potential harm to healthy cells, which is crucial in enhancing patient safety and treatment efficacy.
Continuous advancements in technology have propelled the development of novel platforms and techniques for producing monoclonal antibodies, leading to improved scalability, higher production yields, and cost efficiencies. This scalability is particularly advantageous in meeting the escalating demand for biologic drugs and personalized medicine. The patent expirations of several major mAbs have paved the way for biosimilar manufacturing research, boosting demand for contract manufacturing services to provide cost-effective alternatives.
Competitive Landscape
The presence of key players competing for a significant antibody contract manufacturing market share through innovation, capacity expansion, and strategic collaborations characterizes the competitive landscape of the market. Top companies in the antibody contract manufacturing market include Lonza Group, Catalent, Inc., Samsung Biologics, Boehringer Ingelheim, and Thermo Fisher Scientific.
Stiff competition is compelling companies to focus on differentiation strategies, such as offering comprehensive services across the antibody manufacturing value chain, including cell line development, process optimization, and regulatory compliance.
- In July 2023, TVM Capital Life Science and Tillotts Pharma invested US$ 28 million in Mage Biologics with the aim of developing an innovative oral antibody therapy for ulcerative colitis.
Segmentation of Antibody Contract Manufacturing Market Research
-
By Product Type :
- Monoclonal Antibodies
- Antibody Fragments
- Polyclonal Antibodies
- Others
-
By Expression System :
- Mammalian
- Microbial
-
By Company Size :
- Small
- Mid-sized
- Large
- Very Large
-
By Scale of Operation :
- Preclinical
- Clinical
- Commercial
-
By End User :
- Biopharmaceutical Companies
- Research Laboratories
- Others
-
By Region :
- North America
- Latin America
- Europe
- East Asia
- South Asia & Oceania
- Middle East & Africa
Table of Content
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Product Type Innovation / Development Trends 4. Market Background 4.1. Macro-Economic Factors 4.1.1. Rise in Expenditure 4.1.2. Increased Per Capita Expenditure 4.2. Forecast Factors - Relevance & Impact 4.2.1. Product Type in Pipeline 4.2.2. Regulatory Scenario 4.2.3. Mergers and Acquisitions 4.2.4. Collaborative Agreements 4.2.5. Value Chain 4.3. Market Dynamics 4.3.1. Drivers 4.3.2. Restraints 4.3.3. Opportunity Analysis 4.4. COVID19 Crisis Analysis 4.4.1. Current COVID19 Statistics and Probable Future Impact 4.4.2. Current GDP Projection and Probable Impact 4.4.3. Current Economic Projection as Compared to 2008 Economic analysis 4.4.4. COVID19 and Impact Analysis 4.4.4.1. Revenue By Product Type 4.4.4.2. Revenue By Company Scale of Operation 4.4.4.3. Revenue By Expression System 4.4.4.4. Revenue By Scale of Operation 4.4.4.5. Revenue By End User 4.4.4.6. Revenue By Country 4.4.5. 2020 Market Scenario 4.4.6. Quarter by Quarter Forecast 4.4.7. Projected Recovery Quarter 4.4.8. Recovery Scenario – Short term, Midterm and Long Term Impact 5. Market Context 5.1. Adoption and Usage Analysis 5.2. Market Evolution 5.3. Product Type Vs Company Scale of Operation Matrix 5.4. Regulatory Scenario 5.5. Parent Market Analysis 5.6. Key Promotional Strategies by Market Players 6. Global Market - Pricing Analysis 6.1. Regional Pricing Analysis By Product Type 6.2. Pricing Break-up 6.2.1. Manufacturer Level Pricing 6.2.2. Distributor Level Pricing 6.3. Global Average Pricing Analysis Benchmark 7. Global Market Value Analysis 2018 to 2023 and Forecast, 2024 to 2034 7.1. Historical Market Value (US$ Mn) Analysis, 2018 to 2023 7.2. Current and Future Market Value (US$ Mn) Projections, 2024 to 2034 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, By Product Type 8.1. Introduction / Key Findings 8.2. Historical Market Scale of Operation (US$ Mn) Analysis By Product Type, 2018 to 2023 8.3. Current and Future Market Scale of Operation (US$ Mn) Analysis and Forecast By Product Type, 2024 to 2034 8.3.1. Monoclonal Antibodies 8.3.2. Antibody Fragments 8.3.3. Polyclonal Antibodies 8.3.4. Others 8.4. Market Attractiveness Analysis By Product Type 9. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, by Expression System 9.1. Introduction / Key Findings Expression System Scale of Operation, 2018 to 2023 9.2. Current and Future Market Scale of Operation (US$ Mn) Analysis and Forecast By Expression System, 2024 to 2034 9.2.1. Mammalian 9.2.2. Microbial 9.3. Market Attractiveness Analysis By Expression System 10. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, by Company Scale of Operation 10.1. Introduction / Key Findings Company Scale of Operation Scale of Operation, 2018 to 2023 10.2. Current and Future Market Scale of Operation (US$ Mn) Analysis and Forecast By Company Scale of Operation, 2024 to 2034 10.2.1. Small 10.2.2. Mid-Scale of Operationd 10.2.3. Large 10.2.4. Very Large 10.3. Market Attractiveness Analysis By Company Scale of Operation 11. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, by Scale of Operation 11.1. Introduction / Key Findings Scale of Operation, 2018 to 2023 11.2. Current and Future Market Scale of Operation (US$ Mn) Analysis and Forecast By Scale of Operation, 2024 to 2034 11.2.1. Preclinical 11.2.2. Clinical 11.2.3. Commercial 11.3. Market Attractiveness Analysis By Scale of Operation 12. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, by End User 12.1. Introduction / Key Findings 12.2. Historical Market Scale of Operation (US$ Mn) Analysis By End User, 2018 to 2023 12.3. Current and Future Market Scale of Operation (US$ Mn) Analysis and Forecast By End User, 2024 to 2034 12.3.1. Biopharmaceutical Companies 12.3.2. Research Laboratories 12.3.3. Others 12.4. Market Attractiveness Analysis By End User 13. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, by Region 13.1. Introduction 13.2. Historical Market Scale of Operation (US$ Mn) Analysis By Region, 2018 to 2023 13.3. Current Market Scale of Operation (US$ Mn) Analysis and Forecast By Region, 2024 to 2034 13.3.1. North America 13.3.2. Latin America 13.3.3. Europe 13.3.4. East Asia 13.3.5. South Asia 13.3.6. Oceania 13.3.7. Middle East and Africa (MEA) 13.4. Market Attractiveness Analysis By Region 14. North America Market Analysis 2018 to 2023 and Forecast 2024 to 2034 14.1. Introduction 14.2. Historical Market Scale of Operation (US$ Mn) Trend Analysis By Market Taxonomy, 2018 to 2023 14.3. Market Scale of Operation (US$ Mn) Forecast By Market Taxonomy, 2024 to 2034 14.3.1. By Country 14.3.1.1. United States 14.3.1.2. Canada 14.3.2. By Product Type 14.3.3. By Expression System 14.3.4. By Company Scale of Operation 14.3.5. By Scale of Operation 14.3.6. By End User 14.4. Market Attractiveness Analysis 14.5. Market Trends 14.6. Key Market Participants - Intensity Mapping 14.7. Drivers and Restraints - Impact Analysis 15. Europe Market Analysis 2018 to 2023 and Forecast 2024 to 2034 15.1. Introduction 15.2. Historical Market Scale of Operation (US$ Mn) Trend Analysis By Market Taxonomy, 2018 to 2023 15.3. Market Scale of Operation (US$ Mn) Forecast By Market Taxonomy, 2024 to 2034 15.3.1. By Country 15.3.1.1. Germany 15.3.1.2. Italy 15.3.1.3. France 15.3.1.4. United Kingdom 15.3.1.5. Spain 15.3.1.6. Rest of Europe 15.3.2. By Product Type 15.3.3. By Expression System 15.3.4. By Company Scale of Operation 15.3.5. By Scale of Operation 15.3.6. By End User 15.4. Market Attractiveness Analysis 15.5. Market Trends 15.6. Key Market Participants - Intensity Mapping 15.7. Drivers and Restraints - Impact Analysis 16. Middle East and Africa Market Analysis 2018 to 2023 and Forecast 2024 to 2034 16.1. Introduction 16.2. Historical Market Scale of Operation (US$ Mn) Trend Analysis By Market Taxonomy, 2018 to 2023 16.3. Market Scale of Operation (US$ Mn) Forecast By Market Taxonomy, 2024 to 2034 16.3.1. By Country 16.3.1.1. GCC Countries 16.3.1.2. South Africa 16.3.1.3. Rest of Middle East and Africa 16.3.2. By Product Type 16.3.3. By Expression System 16.3.4. By Company Scale of Operation 16.3.5. By Scale of Operation 16.3.6. By End User 16.4. Market Attractiveness Analysis 16.5. Market Trends 16.6. Key Market Participants - Intensity Mapping 16.7. Drivers and Restraints - Impact Analysis 17. Rest of the World Market Analysis 2018 to 2023 and Forecast 2024 to 2034 17.1. Introduction 17.2. Historical Market Scale of Operation (US$ Mn) Trend Analysis By Market Taxonomy, 2018 to 2023 17.3. Market Scale of Operation (US$ Mn) Forecast By Market Taxonomy, 2024 to 2034 17.3.1. By Product Type 17.3.2. By Expression System 17.3.3. By Company Scale of Operation 17.3.4. By Scale of Operation 17.3.5. By End User 17.4. Market Attractiveness Analysis 17.5. Market Trends 17.6. Key Market Participants - Intensity Mapping 17.7. Drivers and Restraints - Impact Analysis 18. Key and Emerging Countries Market Analysis 2018 to 2023 and Forecast 2024 to 2034 18.1. Introduction 18.1.1. Market Value Proportion Analysis, By Key Countries 18.1.2. Global Vs. Country Growth Comparison 18.2. United States Market Analysis 18.2.1. By Product Type 18.2.2. By Expression System 18.2.3. By Company Scale of Operation 18.2.4. By Scale of Operation 18.2.5. By End User 18.3. Canada Market Analysis 18.3.1. By Product Type 18.3.2. By Expression System 18.3.3. By Company Scale of Operation 18.3.4. By Scale of Operation 18.3.5. By End User 18.4. United Kingdom Market Analysis 18.4.1. By Product Type 18.4.2. By Expression System 18.4.3. By Company Scale of Operation 18.4.4. By Scale of Operation 18.4.5. By End User 18.5. Germany Market Analysis 18.5.1. By Product Type 18.5.2. By Expression System 18.5.3. By Company Scale of Operation 18.5.4. By Scale of Operation 18.5.5. By End User 18.6. France Market Analysis 18.6.1. By Product Type 18.6.2. By Expression System 18.6.3. By Company Scale of Operation 18.6.4. By Scale of Operation 18.6.5. By End User 18.7. Italy Market Analysis 18.7.1. By Product Type 18.7.2. By Expression System 18.7.3. By Company Scale of Operation 18.7.4. By Scale of Operation 18.7.5. By End User 18.8. Spain Market Analysis 18.8.1. By Product Type 18.8.2. By Expression System 18.8.3. By Company Scale of Operation 18.8.4. By Scale of Operation 18.8.5. By End User 18.8.6. By End User 18.9. GCC Countries Market Analysis 18.9.1. By Product Type 18.9.2. By Expression System 18.9.3. By Company Scale of Operation 18.9.4. By Scale of Operation 18.9.5. By End User 18.10. South Africa Market Analysis 18.10.1. By Product Type 18.10.2. By Expression System 18.10.3. By Company Scale of Operation 18.10.4. By Scale of Operation 18.10.5. By End User 19. Market Structure Analysis 19.1. Market Analysis by Tier of Companies 19.2. Market Concentration 19.3. Market Share Analysis of Top Players 19.4. Market Presence Analysis 19.4.1. By Regional footprint of Players 19.4.2. Product Type foot print by Players 19.4.3. Channel Foot Print by Players 20. Competition Analysis 20.1. Competition Dashboard 20.2. Competition Benchmarking 20.3. Competition Deep Dive 20.3.1. AMRI 20.3.1.1. Overview 20.3.1.2. Product Type Portfolio 20.3.1.3. Analyst Commentary 20.3.1.4. Key Financials 20.3.1.5. Recent Developments 20.3.1.6. Sales Footprint 20.3.1.7. Strategy Overview 20.3.1.7.1. Marketing Strategy 20.3.1.7.2. Product Type Strategy 20.3.1.7.3. Channel Strategy 20.3.2. AGC Biologics 20.3.2.1. Overview 20.3.2.2. Product Type Portfolio 20.3.2.3. Analyst Commentary 20.3.2.4. Key Financials 20.3.2.5. Recent Developments 20.3.2.6. Sales Footprint 20.3.2.7. Strategy Overview 20.3.2.7.1. Marketing Strategy 20.3.2.7.2. Product Type Strategy 20.3.2.7.3. Channel Strategy 20.3.3. Aldevron 20.3.3.1. Overview 20.3.3.2. Product Type Portfolio 20.3.3.3. Analyst Commentary 20.3.3.4. Key Financials 20.3.3.5. Recent Developments 20.3.3.6. Sales Footprint 20.3.3.7. Strategy Overview 20.3.3.7.1. Marketing Strategy 20.3.3.7.2. Product Type Strategy 20.3.3.7.3. Channel Strategy 20.3.4. Eurofins CDMO 20.3.4.1. Overview 20.3.4.2. Product Type Portfolio 20.3.4.3. Analyst Commentary 20.3.4.4. Key Financials 20.3.4.5. Recent Developments 20.3.4.6. Sales Footprint 20.3.4.7. Strategy Overview 20.3.4.7.1. Marketing Strategy 20.3.4.7.2. Product Type Strategy 20.3.4.7.3. Channel Strategy 20.3.5. Boehringer Ingelheim BioXcellence 20.3.5.1. Overview 20.3.5.2. Product Type Portfolio 20.3.5.3. Analyst Commentary 20.3.5.4. Key Financials 20.3.5.5. Recent Developments 20.3.5.6. Sales Footprint 20.3.5.7. Strategy Overview 20.3.5.7.1. Marketing Strategy 20.3.5.7.2. Product Type Strategy 20.3.5.7.3. Channel Strategy 20.3.6. Lonza 20.3.6.1. Overview 20.3.6.2. Product Type Portfolio 20.3.6.3. Analyst Commentary 20.3.6.4. Key Financials 20.3.6.5. Recent Developments 20.3.6.6. Sales Footprint 20.3.6.7. Strategy Overview 20.3.6.7.1. Marketing Strategy 20.3.6.7.2. Product Type Strategy 20.3.6.7.3. Channel Strategy 20.3.7. Samsung Biologics 20.3.7.1. Overview 20.3.7.2. Product Type Portfolio 20.3.7.3. Analyst Commentary 20.3.7.4. Key Financials 20.3.7.5. Recent Developments 20.3.7.6. Sales Footprint 20.3.7.7. Strategy Overview 20.3.7.7.1. Marketing Strategy 20.3.7.7.2. Product Type Strategy 20.3.7.7.3. Channel Strategy 20.3.8. WuXi Biologics. 20.3.8.1. Overview 20.3.8.2. Product Type Portfolio 20.3.8.3. Analyst Commentary 20.3.8.4. Key Financials 20.3.8.5. Recent Developments 20.3.8.6. Sales Footprint 20.3.8.7. Strategy Overview 20.3.8.7.1. Marketing Strategy 20.3.8.7.2. Product Type Strategy 20.3.8.7.3. Channel Strategy 20.3.9. Charles River Laboratories 20.3.9.1. Overview 20.3.9.2. Product Type Portfolio 20.3.9.3. Analyst Commentary 20.3.9.4. Key Financials 20.3.9.5. Recent Developments 20.3.9.6. Sales Footprint 20.3.9.7. Strategy Overview 20.3.9.7.1. Marketing Strategy 20.3.9.7.2. Product Type Strategy 20.3.9.7.3. Channel Strategy 20.3.10. FUJIFILM Holdings Corporation 20.3.10.1. Overview 20.3.10.2. Product Type Portfolio 20.3.10.3. Analyst Commentary 20.3.10.4. Key Financials 20.3.10.5. Recent Developments 20.3.10.6. Sales Footprint 20.3.10.7. Strategy Overview 20.3.10.7.1. Marketing Strategy 20.3.10.7.2. Product Type Strategy 20.3.10.7.3. Channel Strategy 20.3.11. Cytovance Biologics, Inc. 20.3.11.1. Overview 20.3.11.2. Product Type Portfolio 20.3.11.3. Analyst Commentary 20.3.11.4. Key Financials 20.3.11.5. Recent Developments 20.3.11.6. Sales Footprint 20.3.11.7. Strategy Overview 20.3.11.7.1. Marketing Strategy 20.3.11.7.2. Product Type Strategy 20.3.11.7.3. Channel Strategy 20.3.12. Thermo Fisher Scientific 20.3.12.1. Overview 20.3.12.2. Product Type Portfolio 20.3.12.3. Analyst Commentary 20.3.12.4. Key Financials 20.3.12.5. Recent Developments 20.3.12.6. Sales Footprint 20.3.12.7. Strategy Overview 20.3.12.7.1. Marketing Strategy 20.3.12.7.2. Product Type Strategy 20.3.12.7.3. Channel Strategy 20.3.13. Labcorp Drug Development 20.3.13.1. Overview 20.3.13.2. Product Type Portfolio 20.3.13.3. Analyst Commentary 20.3.13.4. Key Financials 20.3.13.5. Recent Developments 20.3.13.6. Sales Footprint 20.3.13.7. Strategy Overview 20.3.13.7.1. Marketing Strategy 20.3.13.7.2. Product Type Strategy 20.3.13.7.3. Channel Strategy 20.3.14. Catalent, Inc. 20.3.14.1. Overview 20.3.14.2. Product Type Portfolio 20.3.14.3. Analyst Commentary 20.3.14.4. Key Financials 20.3.14.5. Recent Developments 20.3.14.6. Sales Footprint 20.3.14.7. Strategy Overview 20.3.14.7.1. Marketing Strategy 20.3.14.7.2. Product Type Strategy 20.3.14.7.3. Channel Strategy 20.3.15. Emergent BioSolutions 20.3.15.1. Overview 20.3.15.2. Product Type Portfolio 20.3.15.3. Analyst Commentary 20.3.15.4. Key Financials 20.3.15.5. Recent Developments 20.3.15.6. Sales Footprint 20.3.15.7. Strategy Overview 20.3.15.7.1. Marketing Strategy 20.3.15.7.2. Product Type Strategy 20.3.15.7.3. Channel Strategy 20.3.16. •KBI Biopharma 20.3.16.1. Overview 20.3.16.2. Product Type Portfolio 20.3.16.3. Analyst Commentary 20.3.16.4. Key Financials 20.3.16.5. Recent Developments 20.3.16.6. Sales Footprint 20.3.16.7. Strategy Overview 20.3.16.7.1. Marketing Strategy 20.3.16.7.2. Product Type Strategy 20.3.16.7.3. Channel Strategy 20.3.17. Novasep 20.3.17.1. Overview 20.3.17.2. Product Type Portfolio 20.3.17.3. Analyst Commentary 20.3.17.4. Key Financials 20.3.17.5. Recent Developments 20.3.17.6. Sales Footprint 20.3.17.7. Strategy Overview 20.3.17.7.1. Marketing Strategy 20.3.17.7.2. Product Type Strategy 20.3.17.7.3. Channel Strategy 20.3.18. Nitto Avecia Pharma Services 20.3.18.1. Overview 20.3.18.2. Product Type Portfolio 20.3.18.3. Analyst Commentary 20.3.18.4. Key Financials 20.3.18.5. Recent Developments 20.3.18.6. Sales Footprint 20.3.18.7. Strategy Overview 20.3.18.7.1. Marketing Strategy 20.3.18.7.2. Product Type Strategy 20.3.18.7.3. Channel Strategy 20.3.19. Pierre Fabre 20.3.19.1. Overview 20.3.19.2. Product Type Portfolio 20.3.19.3. Analyst Commentary 20.3.19.4. Key Financials 20.3.19.5. Recent Developments 20.3.19.6. Sales Footprint 20.3.19.7. Strategy Overview 20.3.19.7.1. Marketing Strategy 20.3.19.7.2. Product Type Strategy 20.3.19.7.3. Channel Strategy 20.3.20. Samsung BioLogics 20.3.20.1. Overview 20.3.20.2. Product Type Portfolio 20.3.20.3. Analyst Commentary 20.3.20.4. Key Financials 20.3.20.5. Recent Developments 20.3.20.6. Sales Footprint 20.3.20.7. Strategy Overview 20.3.20.7.1. Marketing Strategy 20.3.20.7.2. Product Type Strategy 20.3.20.7.3. Channel Strategy 20.3.21. Synthon 20.3.21.1. Overview 20.3.21.2. Product Type Portfolio 20.3.21.3. Analyst Commentary 20.3.21.4. Key Financials 20.3.21.5. Recent Developments 20.3.21.6. Sales Footprint 20.3.21.7. Strategy Overview 20.3.21.7.1. Marketing Strategy 20.3.21.7.2. Product Type Strategy 20.3.21.7.3. Channel Strategy 20.3.22. AbbVie, Inc. 20.3.22.1. Overview 20.3.22.2. Product Type Portfolio 20.3.22.3. Analyst Commentary 20.3.22.4. Key Financials 20.3.22.5. Recent Developments 20.3.22.6. Sales Footprint 20.3.22.7. Strategy Overview 20.3.22.7.1. Marketing Strategy 20.3.22.7.2. Product Type Strategy 20.3.22.7.3. Channel Strategy 21. Assumptions and Acronyms Used 22. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Market Scale of Operation (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Product Type
Table 02: Global Market Scale of Operation (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Expression System
Table 03: Global Market Scale of Operation (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Company Scale of Operation
Table 04: Global Market Scale of Operation (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Scale of Operation
Table 05: Global Market Scale of Operation (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By End User
Table 06: Global Market Scale of Operation (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Scale of Operation Age Group
Table 07: Global Market Scale of Operation (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Region
Table 08: North America Market Scale of Operation (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Country
Table 09: North America Market Scale of Operation (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Product Type
Table 10: North America Market Scale of Operation (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Company Scale of Operation
Table 11: North America Market Scale of Operation (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Expression System
Table 12: North America Market Scale of Operation (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Scale of Operation
Table 13: North America Market Scale of Operation (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By End User
Table 14: Europe Market Scale of Operation (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Country
Table 15: Europe Market Scale of Operation (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Product Type
Table 16: Europe Market Scale of Operation (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Company Scale of Operation
Table 17: Europe Market Scale of Operation (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Expression System
Table 18: Europe Market Scale of Operation (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Scale of Operation
Table 19: Europe Market Scale of Operation (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By End User
Table 20: Middle East and Africa Market Scale of Operation (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Country
Table 21: Middle East and Africa Market Scale of Operation (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Product Type
Table 22: Middle East and Africa Market Scale of Operation (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Company Scale of Operation
Table 23: Middle East and Africa Market Scale of Operation (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Expression System
Table 24: Middle East and Africa Market Scale of Operation (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Scale of Operation
Table 25: Middle East and Africa Market Scale of Operation (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By End User
Table 26: Rest of the World Market Scale of Operation (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Product Type
Table 27: Rest of the World Market Scale of Operation (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Company Scale of Operation
Table 28: Rest of the World Market Scale of Operation (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Expression System
Table 29: Rest of the World Market Scale of Operation (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Scale of Operation
Table 30: Rest of the World Market Scale of Operation (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By End User
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Market Value (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034
Figure 02: Global Market Absolute $ Opportunity, 2024 to 2034
Figure 03: Global Market Share Analysis (%), By Product Type, 2024 & 2034
Figure 04: Global Market Y-o-Y Analysis (%), By Product Type, 2024 to 2034
Figure 05: Global Market Attractiveness Analysis By Product Type, 2024 to 2034
Figure 06: Global Market Share Analysis (%), By Expression System, 2024 & 2034
Figure 07: Global Market Y-o-Y Analysis (%), By Expression System, 2024 to 2034
Figure 08: Global Market Attractiveness Analysis By Expression System, 2024 to 2034
Figure 09: Global Market Share Analysis (%), By Company Scale of Operation, 2024 & 2034
Figure 10: Global Market Y-o-Y Analysis (%), By Company Scale of Operation, 2024 to 2034
Figure 11: Global Market Attractiveness Analysis By Company Scale of Operation, 2024 to 2034
Figure 12: Global Market Share Analysis (%), By Scale of Operation, 2024 & 2034
Figure 13: Global Market Y-o-Y Analysis (%), By Scale of Operation, 2024 to 2034
Figure 14: Global Market Attractiveness Analysis By Scale of Operation, 2024 to 2034
Figure 15: Global Market Share Analysis (%), By End User, 2024 & 2034
Figure 16: Global Market Y-o-Y Analysis (%), By End User , 2024 to 2034
Figure 17: Global Market Attractiveness Analysis, By End User, 2024 to 2034
Figure 18: Global Market Share Analysis (%), By Scale of Operation Age Group, 2024 & 2034
Figure 19: Global Market Y-o-Y Analysis (%), By Scale of Operation Age Group, 2024 to 2034
Figure 20: Global Market Attractiveness Analysis By Scale of Operation Age Group, 2024 to 2034
Figure 21: Global Market Share Analysis (%), By Region, 2024 & 2034
Figure 22: Global Market Y-o-Y Analysis (%), By Region, 2024 to 2034
Figure 23: Global Market Attractiveness Analysis, By Region, 2024 to 2034
Figure 24: North America Market Value Share, By Product Type, 2024 (E)
Figure 25: North America Market Value Share, By Company Scale of Operations 2024 (E)
Figure 26: North America Market Value Share, By Expression System, 2024 (E)
Figure 27: North America Market Value Share, By Scale of Operation, 2024 (E)
Figure 28: North America Market Value Share, By End User, 2024 (E)
Figure 29: North America Market Value Share, By Country, 2024 (E)
Figure 30: North America Market Value (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034
Figure 31: North America Market Attractiveness Analysis By Product Type, 2024 to 2034
Figure 32: North America Market Attractiveness Analysis By Company Scale of Operation, 2024 to 2034
Figure 33: North America Market Attractiveness Analysis By Expression System, 2024 to 2034
Figure 34: North America Market Attractiveness Analysis By Scale of Operation, 2024 to 2034
Figure 35: North America Market Attractiveness Analysis By End User, 2024 to 2034
Figure 36: North America Market Attractiveness Analysis By Country, 2024 to 2034
Figure 37: Europe Market Value Share, By Product Type, 2024 (E)
Figure 38: Europe Market Value Share, By Company Scale of Operations 2024 (E)
Figure 39: Europe Market Value Share, By Expression System, 2024 (E)
Figure 40: Europe Market Value Share, By Scale of Operation, 2024 (E)
Figure 41: Europe Market Value Share, By End User, 2024 (E)
Figure 42: Europe Market Value Share, By Country, 2024 (E)
Figure 43: Europe Market Value (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034
Figure 44: Europe Market Attractiveness Analysis By Product Type, 2024 to 2034
Figure 45: Europe Market Attractiveness Analysis By Company Scale of Operation, 2024 to 2034
Figure 46: Europe Market Attractiveness Analysis By Expression System, 2024 to 2034
Figure 47: Europe Market Attractiveness Analysis By Scale of Operation, 2024 to 2034
Figure 48: Europe Market Attractiveness Analysis By Expression System, 2024 to 2034
Figure 49: Europe Market Attractiveness Analysis By Country, 2024 to 2034
Figure 50: Middle East and Africa Market Value Share, By Product Type, 2024 (E)
Figure 51: Middle East and Africa Market Value Share, By Company Scale of Operation, 2024 (E)
Figure 52: Middle East and Africa Market Value Share, By Expression System, 2024 (E)
Figure 53: Middle East and Africa Market Value Share, By Scale of Operation, 2024 (E)
Figure 54: Middle East and Africa Market Value Share, By End User, 2024 (E)
Figure 55: Middle East and Africa Market Value Share, By Country, 2024 (E)
Figure 56: Middle East and Africa Market Value (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034
Figure 57: Middle East and Africa Market Attractiveness Analysis By Product Type, 2024 to 2034
Figure 58: Middle East and Africa Market Attractiveness Analysis By Company Scale of Operation, 2024 to 2034
Figure 59: Middle East and Africa Market Attractiveness Analysis By Expression System, 2024 to 2034
Figure 60: Middle East and Africa Market Attractiveness Analysis By Scale of Operation, 2024 to 2034
Figure 61: Middle East and Africa Market Attractiveness Analysis By End User, 2024 to 2034
Figure 62: Middle East and Africa Market Attractiveness Analysis By Country, 2024 to 2034
Figure 63: Rest of the World Market Value Share, By Product Type, 2024 (E)
Figure 64: Rest of the World Market Value Share, By Company Scale of Operations 2024 (E)
Figure 65: Rest of the World Market Value Share, By Expression System, 2024 (E)
Figure 66: Rest of the World Market Value Share, By Scale of Operation, 2024 (E)
Figure 67: Rest of the World Market Value Share, By End User, 2024 (E)
Figure 68: Rest of the World Market Value (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034
Figure 69: Rest of the World Market Attractiveness Analysis By Product Type, 2024 to 2034
Figure 70: Rest of the World Market Attractiveness Analysis By Company Scale of Operation, 2024 to 2034
Figure 71: Rest of the World Market Attractiveness Analysis By Expression System, 2024 to 2034
Figure 72: Rest of the World Market Attractiveness Analysis By Scale of Operation, 2024 to 2034
Figure 73: Rest of the World Market Attractiveness Analysis By End User, 2024 to 2034
Figure 74: United States Market Value Share, By Product Type, 2024 & 2034
Figure 75: United States Market Value Share, By Company Scale of Operation, 2024 & 2034
Figure 76: United States Market Value Share, By Expression System, 2024 & 2034
Figure 77: United States Market Value Share, By Scale of Operation Age Group, 2024 & 2034
Figure 78: United States Market Value Share, By End User, 2024 & 2034
Figure 79: United States Market Value Analysis (US$ Mn), 2024 & 2034
Figure 80: Canada Market Value Share, By Product Type, 2024 & 2034
Figure 81: Canada Market Value Share, By Company Scale of Operation, 2024 & 2034
Figure 82: Canada Market Value Share, By Expression System, 2024 & 2034
Figure 83: Canada Market Value Share, By Scale of Operation Age Group, 2024 & 2034
Figure 84: Canada Market Value Share, By End User, 2024 & 2034
Figure 85: Canada Market Value Analysis (US$ Mn), 2024 & 2034
Figure 86: United Kingdom Market Value Share, By Product Type, 2024 & 2034
Figure 87: United Kingdom Market Value Share, By Company Scale of Operation, 2024 & 2034
Figure 88: United Kingdom Market Value Share, By Expression System, 2024 & 2034
Figure 89: United Kingdom Market Value Share, By Scale of Operation Age Group, 2024 & 2034
Figure 90: United Kingdom Market Value Share, By End User, 2024 & 2034
Figure 91: United Kingdom Market Value Analysis (US$ Mn), 2024 & 2034
Figure 92: Germany Market Value Share, By Product Type, 2024 & 2034
Figure 93: Germany Market Value Share, By Company Scale of Operation, 2024 & 2034
Figure 94: Germany Market Value Share, By Expression System, 2024 & 2034
Figure 95: Germany Market Value Share, By Scale of Operation Age Group, 2024 & 2034
Figure 96: Germany Market Value Share, By End User, 2024 & 2034
Figure 97: Germany Market Value Analysis (US$ Mn), 2024 & 2034
Figure 98: France Market Value Share, By Product Type, 2024 & 2034
Figure 99: France Market Value Share, By Company Scale of Operation, 2024 & 2034
Figure 100: France Market Value Share, By Expression System, 2024 & 2034
Figure 101: France. Market Value Share, By Scale of Operation Age Group, 2024 & 2034
Figure 102: France Market Value Share, By End User, 2024 & 2034
Figure 103: France Market Value Analysis (US$ Mn), 2024 & 2034
Figure 104: Italy Market Value Share, By Product Type, 2024 & 2034
Figure 105: Italy Market Value Share, By Company Scale of Operation, 2024 & 2034
Figure 106: Italy Market Value Share, By Expression System, 2024 & 2034
Figure 107: Italy Market Value Share, By Scale of Operation Age Group, 2024 & 2034
Figure 108: Italy Market Value Share, By End User, 2024 & 2034
Figure 109: Italy Market Value Analysis (US$ Mn), 2024 & 2034
Figure 110: Spain Market Value Share, By Product Type, 2024 & 2034
Figure 111: Spain Market Value Share, By Company Scale of Operation, 2024 & 2034
Figure 112: Spain Market Value Share, By Expression System, 2024 & 2034
Figure 113: Spain Market Value Share, By Scale of Operation Age Group, 2024 & 2034
Figure 114: Spain Market Value Share, By End User, 2024 & 2034
Figure 115: Spain Market Value Analysis (US$ Mn), 2024 & 2034
Figure 116: GCC Countries. Market Value Share, By Product Type, 2024 & 2034
Figure 117: GCC Countries Market Value Share, By Company Scale of Operation, 2024 & 2034
Figure 118: GCC Countries Market Value Share, By Expression System, 2024 & 2034
Figure 119: GCC Countries Market Value Share, By Scale of Operation, 2024 & 2034
Figure 120: GCC Countries Market Value Share, By End User, 2024 & 2034
Figure 121: GCC Countries Market Value Analysis (US$ Mn), 2024 & 2034
Figure 122: South Africa Market Value Share, By Product Type, 2024 & 2034
Figure 123: South Africa Market Value Share, By Company Scale of Operation, 2024 & 2034
Figure 124: South Africa Market Value Share, By Expression System, 2024 & 2034
Figure 125: South Africa Market Value Share, By Scale of Operation Age Group, 2024 & 2034
Figure 126: South Africa Market Value Share, By End User, 2024 & 2034
Figure 127: South Africa Market Value Analysis (US$ Mn), 2024 & 2034
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
What is the estimated value of the antibody contract manufacturing market in 2024?
The global antibody contract manufacturing market is estimated at US$ 6.1 billion in 2024.
What is the demand forecast for antibody contract manufacturing?
Demand for antibody contract manufacturing is forecasted to reach a market value of US$ 20.85 billion by 2034-end.
Which segment accounts for a leading market share?
Monoclonal antibodies are forecasted to account for 90.6% share of the global market by 2034.
What is the demand growth projection for antibody contract manufacturing?
Revenue from antibody contract manufacturing is projected to rise at a CAGR of 13.1% through 2034.
At what rate is the mammalian expression system segment predicted to grow?
The mammalian expression system segment is forecasted to expand at a CAGR of 13.3% over the forecast period.
What is the predicted growth rate for the market in East Asia?
The market in East Asia is projected to expand at 16.9% CAGR from 2024 to 2034.
What is the expected growth rate for the market in North America?
The market in North America is projected to advance at a CAGR of 11.3% over the next 10 years.
Antibody Contract Manufacturing Market